SLC5A2 and hydrops fetalis: In our meta-analysis, the pooled results of 4 studies and 3738 patients with HFpEF found a 25% relative risk reduction in the composite outcome of cardiovascular death or HF hospitalizations/urgent visits among those randomized to SGLT2 inhibitors.